20.74

0.92% +0.19

Pre-market: 20.69 -0.05 -0.24%

Cassava Sciences Inc (SAVA)

Overview News Price History Option Chain Why SAVA Down? Discussions Forecast Stock Split Dividend History

Cassava Sciences Inc stock is currently priced at $20.74, with a 24-hour trading volume of 476.34K. It has seen a +0.92% increased in the last 24 hours and a +4.69% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $20.70 pivot point. If it approaches the $21.06 resistance level, significant changes may occur.

Previous Close:

$20.55

Open:

$20.68

24h Volume:

476.34K

Market Cap:

$896.92M

Revenue:

Net Income/Loss:

$-97.22M

P/E Ratio:

-9.4703

EPS:

-2.19

Net Cash Flow:

$-82.44M

1W Performance:

-2.49%

1M Performance:

+4.69%

6M Performance:

+40.42%

1Y Performance:

-9.15%

1D Range:

$20.17

$20.84

52W Range:

$12.32

$32.10

Cassava Sciences Inc Stock (SAVA) Company Profile

Name

Cassava Sciences Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

512-501-2444

Address

7801 North Capital of Texas Highway, Suite 260, Austin, TX

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

SAVA's Discussions on Twitter

Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-16-22	Downgrade	B. Riley Securities	Buy → Neutral
Jul-15-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-07-21	Reiterated	Maxim Group	Buy
Apr-27-21	Initiated	B. Riley Securities	Buy
Feb-16-21	Reiterated	H.C. Wainwright	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-23-20	Upgrade	H.C. Wainwright	Neutral → Buy
May-18-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-20	Downgrade	Maxim Group	Buy → Hold
Jan-10-20	Reiterated	Maxim Group	Buy

View All

Cassava Sciences Inc Stock (SAVA) Latest News

Redemption Date Announced for Warrants

GlobeNewswire Inc.

Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

GlobeNewswire Inc.

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

GlobeNewswire Inc.

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

GlobeNewswire Inc.

Brian's Big Idea on Low Priced Stocks

Zacks Investment Research

Cassava Sciences Inc Stock (SAVA) Financials Data

Cassava Sciences Inc (SAVA) Net Income 2024

SAVA net income (TTM) was -$97.22 million for the quarter ending December 31, 2023, a -27.50% decrease year-over-year.

Cassava Sciences Inc (SAVA) Cash Flow 2024

SAVA recorded a free cash flow (TTM) of -$82.44 million for the quarter ending December 31, 2023, a -2.76% decrease year-over-year.

Cassava Sciences Inc (SAVA) Earnings per Share 2024

SAVA earnings per share (TTM) was -$2.32 for the quarter ending December 31, 2023, a -22.11% decline year-over-year.

Cassava Sciences Inc Stock (SAVA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Schoen Eric	Chief Financial Officer	Apr 17 '24	Option Exercise	22.00	1,500	33,000	21,300
ROBERTSON SANFORD	Director	Aug 23 '23	Buy	17.45	30,000	523,500	886,851
Barry Richard	Director	Aug 22 '23	Buy	16.65	16,571	275,907	293,477
Barry Richard	Director	Aug 21 '23	Buy	16.80	1,906	32,021	276,906
SCANNON PATRICK J MD PHD	Director	Jun 12 '23	Option Exercise	0.95	1,000	950	1,000
BARBIER REMI	President and CEO	May 24 '23	Option Exercise	16.87	71,428	1,204,990	782,002
BARBIER REMI	President and CEO	May 24 '23	Option Exercise	16.87	14,285	240,988	390,397
ROBERTSON SANFORD	Director	May 10 '23	Option Exercise	17.79	9,284	165,170	856,851
GUSSIN ROBERT Z	Director	May 01 '23	Option Exercise	17.79	9,284	165,170	17,694

Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.